J Pain Res. 2025 Oct 16;18:5455-5465. doi: 10.2147/JPR.S526655. eCollection 2025.
ABSTRACT
INTRODUCTION: Increasing evidence has indicated that prescription opioid use is associated with poor prognosis in patients with fibromyalgia. However, it remains unknown whether there are causal associations between prescription opioid and fibromyalgia.
METHODS: We performed a bidirectional two-sample MR analysis using genetic variants associated with prescription pain medication use and fibromyalgia from genome-wide association studies (GWAS). Multivariable Mendelian randomization (MVMR) was further employed to ascertain the causal relationship, incorporating confounders such as major depressive disorder (MDD), anxiety disorders (ADs) and insomnia. A mediation MR analysis was conducted to assess their potential mediating roles.
RESULTS: The forward two-sample Mendelian analysis revealed a positive causal role in the contribution of prescription opioid use to fibromyalgia, as indicated by the Inverse Variance Weighted (IVW) method (OR = 1.42, 95% CI: 1.17, 1.72, p = 3.55E-04) and the Weighted Median method (OR = 1.40, 95% CI: 1.07, 1.83; p = 0.01). In MVMR, the association remained after accounting for MDD, ADs and insomnia, none of which exhibited mediating effects. In the reverse MR analysis, which assessed whether fibromyalgia causally affected prescription opioid use, no significant associations were found. No substantial associations were observed between non-opioid pain medications and fibromyalgia.
CONCLUSION: Our findings provide genetic evidence supporting causal relationship for prescription opioid use on a high risk of fibromyalgia. This association remains robust after adjustment for MDD, ADs and insomnia. Given the potential for opioid prescriptions to increase the risk of developing fibromyalgia, clinicians should prioritize alternative, evidence-based pain management strategies.
PMID:41127854 | PMC:PMC12537515 | DOI:10.2147/JPR.S526655
Recent Comments